Jacobs Levy Equity Management
CNCE

Jacobs Levy Equity Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Jacobs Levy Equity Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-366,448
Closed -$1.2M – 1114
2021
Q3 		$1.2M Buy
366,448
+29,012
+9% +$102K 0.01% 719
2021
Q2 		$1.42M Buy
337,436
+222,504
+194% +$942K 0.01% 669
2021
Q1 		$574K Sell
114,932
-80,868
-41% -$654K ﹤0.01% 842
2020
Q4 		$2.48M Sell
195,800
-1,634
-0.8% -$18.6K 0.02% 527
2020
Q3 		$1.94M Sell
197,434
-33,826
-15% -$333K 0.02% 526
2020
Q2 		$2.3M Sell
231,260
-8,947
-4% -$85.8K 0.02% 504
2020
Q1 		$2.12M Buy
240,207
+23,295
+11% +$230K 0.03% 462
2019
Q4 		$2M Buy
216,912
+130,612
+151% +$926K 0.02% 543
2019
Q3 		$507K Buy
86,300
+47,000
+120% +$499K 0.01% 718
2019
Q2 		$472K Buy
+39,300
New +$423K 0.01% 748
2017
Q1 		– Sell
-58,314
Closed -$600K – 1032
2016
Q4 		$600K Buy
58,314
+26,462
+83% +$242K 0.01% 643
2016
Q3 		$322K Buy
31,852
+5,016
+19% +$54.8K 0.01% 794
2016
Q2 		$301K Buy
26,836
+14,996
+127% +$191K 0.01% 882
2016
Q1 		$162K Buy
+11,840
New +$170K ﹤0.01% 997

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management's CNCE Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2021, closing a stake of 366,448 shares — an estimated $1.2M sold.

Jacobs Levy Equity Management first reported a position in CNCE in Q1 2016 and held it in 14 quarters. The position peaked at $2.48M in Q4 2020. 52 funds tracked by Wall St. Rank hold CNCE as of Q4 2021.

  • Jacobs Levy Equity Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 366,448 Concert Pharmaceuticals, Inc. shares in Q4 2021, an estimated $1.2M.
  • Jacobs Levy Equity Management first reported a position in Concert Pharmaceuticals, Inc. in Q1 2016 and held it in 14 quarters.
  • Jacobs Levy Equity Management's Concert Pharmaceuticals, Inc. position peaked at $2.48M in Q4 2020.
  • 52 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.